At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Dirk Arnold presents results from a phase III clinical trial showing that combination treatment with bevacizumab and standard chemotherapy in the second line setting extends overall survival in patients with advanced colorectal cancer after receiving bevacizumab combination treatment.